Tirzepatide-based medicines Mounjaro for diabetes and Zepbound for obesity have led the charge, contributing $3.1 billion and $1.2 billion to Lilly's revenues for the period, respectively ...
Titles with fewer than 7 critic reviews are excluded.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback